On this page
The evidence at a glance
The study, in context
The 2020 study found different age patterns in circulating and muscle MOTS-c measures in healthy men. It did not administer a MOTS-c product or establish that raising a blood value improves health.
D’Souza et al.: MOTS-c in Skeletal Muscle of Healthy Aging Men (2020)
- Study design
- Cross-sectional observational human tissue and plasma study.
- Who or what was studied
- Healthy young, middle-aged and older men.
- What was measured
- Circulating and skeletal-muscle MOTS-c measures and muscle characteristics.
- What it found
- Plasma MOTS-c was lower with age while muscle expression was higher in older groups.
- Important limit
- Associations across age groups; no peptide treatment, causal replacement test or universal target concentration.
The sample compartment is part of the finding
A blood measurement and a muscle measurement are not interchangeable versions of one simple number. They can reflect different processes. When a claim says that a peptide falls with age, ask where it was measured and in whom. The study is useful because it makes that question concrete rather than reducing aging to a single deficiency narrative.
Another measurement context
The metformin and MOTS-c biomarker study measured blood levels in a different clinical setting. It did not administer MOTS-c as the randomized treatment. Read the intervention and the measured outcome separately before interpreting either paper as evidence for a commercial product.
A comparison between groups is not a personal trajectory
Cross-sectional work compares people observed at one stage in their lives. It does not necessarily show how the same individual’s values changed over decades. Differences between groups can generate hypotheses without proving what caused them. That is a reason to be cautious about turning an age association into a recommendation to replace something.
There was no replacement experiment
The researchers did not demonstrate that treating a low measured value improves a human outcome. A biomarker association and a therapeutic target require different kinds of evidence. Ask whether a proposed blood test has an established role in deciding treatment, and what evidence connects any target range with something that matters to a patient.
Before paying for a biomarker test
Ask what decision would change in response to the result. A useful test needs more than a measurable value or a comparison with younger people; the interpretation and consequence should be clear. If a provider proposes treatment based on the result, ask which evidence connects that decision with a meaningful outcome. Also ask what uncertainty remains if different tissues show different patterns. This does not require rejecting all biomarker research. It requires preserving the distinction between a research association, a clinically useful test and a treatment strategy that has actually been evaluated.
Read the exercise record alongside this one
The exercise evidence guide and the endogenous-peptide guide address related but separate observations. A body-produced peptide response should not be presented as equivalent to a commercial injection. Likewise, a mouse treatment experiment does not resolve the meaning of a human tissue association. The value of a research library is in preserving those distinctions.
A better care question than a number alone
The MyNuvara Health and Promise reviews describe service commitments, not validation of biomarker-guided treatment. Ask the clinician how a test would change a decision, what alternatives are relevant and how benefit would be assessed. A quote becomes useful only after the clinical question and exact formulation have been made explicit.
Read the source
Research findings and provider statements are different evidence.